5,700,000 Shares in Terns Pharmaceuticals, Inc. $TERN Acquired by Commodore Capital LP

Commodore Capital LP acquired a new position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 5,700,000 shares of the company’s stock, valued at approximately $42,807,000. Terns Pharmaceuticals makes up about 2.1% of Commodore Capital LP’s investment portfolio, making the stock its 18th biggest position. Commodore Capital LP owned about 6.33% of Terns Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also made changes to their positions in the business. Cubist Systematic Strategies LLC grew its holdings in Terns Pharmaceuticals by 136.8% during the 1st quarter. Cubist Systematic Strategies LLC now owns 28,327 shares of the company’s stock worth $78,000 after acquiring an additional 16,363 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Terns Pharmaceuticals during the first quarter valued at approximately $51,000. Goldman Sachs Group Inc. increased its holdings in shares of Terns Pharmaceuticals by 21.0% in the first quarter. Goldman Sachs Group Inc. now owns 415,021 shares of the company’s stock valued at $1,145,000 after purchasing an additional 71,971 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Terns Pharmaceuticals by 3.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,633,349 shares of the company’s stock worth $6,094,000 after buying an additional 59,145 shares in the last quarter. Finally, Candriam S.C.A. boosted its position in Terns Pharmaceuticals by 9.9% in the 2nd quarter. Candriam S.C.A. now owns 2,368,235 shares of the company’s stock valued at $8,834,000 after buying an additional 214,266 shares during the last quarter. 98.26% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently issued reports on TERN. Citizens Jmp upped their price target on Terns Pharmaceuticals from $35.00 to $57.00 and gave the company a “market outperform” rating in a research note on Thursday, December 11th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Terns Pharmaceuticals in a research report on Monday, December 29th. Oppenheimer raised their price objective on shares of Terns Pharmaceuticals from $28.00 to $58.00 and gave the company an “outperform” rating in a research note on Tuesday, December 9th. Truist Financial increased their price target on Terns Pharmaceuticals from $35.00 to $56.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Finally, Wall Street Zen upgraded Terns Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, February 14th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Terns Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $58.11.

Insider Activity

In other news, insider Emil Kuriakose sold 1,155 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $38.57, for a total value of $44,548.35. Following the completion of the transaction, the insider owned 50,365 shares in the company, valued at $1,942,578.05. This represents a 2.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Amy L. Burroughs sold 71,339 shares of the stock in a transaction on Monday, January 5th. The stock was sold at an average price of $38.10, for a total transaction of $2,718,015.90. Following the sale, the chief executive officer directly owned 138,976 shares of the company’s stock, valued at $5,294,985.60. This represents a 33.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 155,826 shares of company stock worth $5,882,597 in the last quarter. 1.50% of the stock is currently owned by company insiders.

Terns Pharmaceuticals Trading Up 5.2%

TERN stock opened at $46.52 on Friday. Terns Pharmaceuticals, Inc. has a 1-year low of $1.87 and a 1-year high of $48.26. The firm has a market cap of $4.83 billion, a PE ratio of -45.17 and a beta of -0.31. The business’s 50-day moving average price is $38.76 and its two-hundred day moving average price is $26.24.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.